UNSPSC 51123301: Asocainol

This classification denotes an antiarrhythmic agent with the molecular formula C27H31NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) J40338OKKT, chemically known as (+-)-6,7,8,9-tetrahydro-2,12-dimethoxy-7-methyl-6-phenethyl-5h-dibenz(d,f)azonin-1-ol but more generally known as asocainol, which bears US NIH Compound Identifier 71161. Asocainol most often comes in base and hydrochloride forms.

UNSPSC 51123301 Asocainol, a Commodity code, encompasses emergency and acute-care medications that state and local governments procure for fire rescue services, health agencies, and multistate cooperative purchasing programs. Recent solicitations show state and local buyers acquiring specific medication line items—epinephrine injections, adenosine vials, labetalol, diltiazem, and generic multi-source pharmaceuticals—through sealed competitive bids and cooperative agreements, with vendors required to meet FDA compliance, cGMP certification, expiration-date minimums, safety documentation, and accessibility standards. Issuing bodies include municipal fire rescue departments (Tampa Fire Rescue via the City of Tampa Purchasing Department), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across participating jurisdictions including Minnesota and Oregon). The City of Tampa and MMCAP represent repeat procurement activity in this commodity space, with MMCAP administering agreements across multiple state members.

Recent opportunities span Florida, Texas, and the Upper Midwest. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications on April 24, 2026, with a due date of April 8, 2026 (estimated contract value $40,000, one-year term with renewal options and a 5 percent SLBE bid discount). The Minnesota Department of Administration's Office of State Procurement posted MMCAP RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with proposals due March 26, 2026, and contract effectiveness July 1, 2026 (two-year term with optional extensions, performance penalties up to $1,500 per violation, 3 percent administrative fee on all purchases). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs for a future Therapeutic Pharmacy Initiative, signaling upstream procurement planning in Texas.